HRP20191461T1 - Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja - Google Patents
Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja Download PDFInfo
- Publication number
- HRP20191461T1 HRP20191461T1 HRP20191461T HRP20191461T1 HR P20191461 T1 HRP20191461 T1 HR P20191461T1 HR P20191461 T HRP20191461 T HR P20191461T HR P20191461 T1 HRP20191461 T1 HR P20191461T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- leukemia
- compound
- use according
- lymphoma
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 13
- -1 amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives Chemical class 0.000 title 1
- 230000001093 anti-cancer Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 208000032839 leukemia Diseases 0.000 claims 7
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 201000011176 T-cell adult acute lymphocytic leukemia Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Claims (14)
1. 3’-Deoksiadenozin-5’-O-[fenil(benziloksi-L-alaninil)] fosfat
ili farmaceutski prihvatljiva sol, ester, sol estera ili solvat njegovog spoja.
2. 3’-Deoksiadenozin-5’-O-[fenil(benziloksi-L-alaninil)] fosfat u skladu s patentnim zahtjevom 1
3. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 za uporabu u vidu lijeka.
4. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 za uporabu u profilaksi ili liječenju raka.
5. Spoj za uporabu u skladu s patentnim zahtjevom 4 za uporabu u ciljanom djelovanju na matične stanice raka prilikom liječenja raka.
6. Spoj za uporabu u skladu s patentnim zahtjevom 5, naznačeno time što je rak izabran od leukemije, limfoma, raka dojke, raka pluća, raka debelog crijeva, raka prostate, raka jajnika, raka kože, raka mokraćnog mjehura, raka žučnih puteva i raka gušterače.
7. Spoj za uporabu u skladu s patentnim zahtjevom 5, naznačeno time što je rak izabran od raka dojke, raka CNS-a, raka debelog crijeva, Ewingovog sarkoma, melanoma, raka jetre, kolangiokarcinoma, raka jajnika, raka gušterače, raka pluća ne-malih stanica, raka mokraćnog mjehura, akutne mijeloidne leukemije, B-akutne limfoblastne leukemije, B-akutne limfoblastne leukemije, multiplog mijeloma i T-akutne limfoblastne leukemije.
8. Spoj za uporabu u skladu s patentnim zahtjevom 4, naznačeno time što je rak izabran iz grupe koja se sastoji od: leukemije, limfoma, multiplog mijeloma, raka pluća (uključujući rak pluća ne-malih stanica i sitnoćelijski rak pluća), raka jetre, raka dojke, raka mokraćnog mjehura, raka prostate, raka glave i vrata, neuroblastoma, sarkoma (uključujući Ewingov sarkom), tiroidnog karcinoma, raka kože (uključujući melanom), oralnog karcinoma skvamoznih stanica, raka mokraćnog mjehura, tumora Leydigovih stanica, raka žučnih puteva, kao što su kolangiokarcinom ili rak žučnog kanala, raka gušterače, raka debelog crijeva, kolorektalnog raka i ginekoloških karcinoma, uključujući rak jajnika, rak endometrija.
9. Spoj za uporabu u skladu s patentnim zahtjevom 8, naznačeno time što je rak leukemija ili limfom.
10. Spoj za uporabu u skladu s patentnim zahtjevom 9, naznačeno time što je leukemija izabrana iz grupe koja sadrži akutnu limfoblastnu leukemiju, akutnu mijelogenu leukemiju, akutnu promijelocitnu leukemiju, akutnu limfocitnu leukemiju, kroničnu mijelogenu leukemiju, kroničnu limfocitnu leukemiju, monoblastnu leukemiju, leukemiju vlasastih stanica, Hodgkinov limfom i ne-Hodgkinov limfom.
11. Spoj za uporabu u skladu s patentnim zahtjevom 10, naznačeno time što je leukemija akutna limfoblastna leukemija.
12. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 4 do 11, naznačeno time što je rak rekurentni ili nesenzitivni rak.
13. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 4 do 11, naznačeno time što je rak metastatski rak.
14. Farmaceutska kompozicija koja sadrži spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 u kombinaciji s farmaceutski prihvatljivim nosačem, razblaživačem ili ekscipijensom.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1421211.2A GB201421211D0 (en) | 2014-11-28 | 2014-11-28 | Chemical compounds |
| GBGB1519316.2A GB201519316D0 (en) | 2015-11-02 | 2015-11-02 | Chemical compounds |
| PCT/GB2015/053628 WO2016083830A1 (en) | 2014-11-28 | 2015-11-27 | New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds |
| EP15804216.8A EP3224268B1 (en) | 2014-11-28 | 2015-11-27 | New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191461T1 true HRP20191461T1 (hr) | 2019-11-15 |
Family
ID=54771155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191461 HRP20191461T1 (hr) | 2014-11-28 | 2019-08-13 | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10570168B2 (hr) |
| EP (2) | EP3683225A1 (hr) |
| JP (2) | JP6646668B2 (hr) |
| KR (2) | KR20230098915A (hr) |
| CN (2) | CN107207554B (hr) |
| AU (2) | AU2015352203B2 (hr) |
| CA (1) | CA2962373C (hr) |
| CL (1) | CL2017001336A1 (hr) |
| CY (1) | CY1122074T1 (hr) |
| DK (1) | DK3224268T3 (hr) |
| EA (1) | EA031727B1 (hr) |
| ES (1) | ES2742167T3 (hr) |
| HR (1) | HRP20191461T1 (hr) |
| HU (1) | HUE046850T2 (hr) |
| IL (4) | IL291927A (hr) |
| LT (1) | LT3224268T (hr) |
| ME (1) | ME03462B (hr) |
| MX (3) | MX2017006942A (hr) |
| PH (1) | PH12017500944A1 (hr) |
| PL (1) | PL3224268T3 (hr) |
| PT (1) | PT3224268T (hr) |
| RS (1) | RS59264B1 (hr) |
| SG (2) | SG11201702369UA (hr) |
| SI (1) | SI3224268T1 (hr) |
| WO (1) | WO2016083830A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029022T2 (en) | 2011-03-01 | 2017-02-28 | Nucana Biomed Ltd | Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer |
| MX2017006942A (es) * | 2014-11-28 | 2017-08-24 | Nucana Biomed Ltd | Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer. |
| GB201522764D0 (en) * | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609601D0 (en) * | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
| CN110669088B (zh) * | 2018-07-02 | 2023-03-28 | 成都阿奇生物医药科技有限公司 | N-(2-乙基胺)苯磺酰胺基虫草素衍生物及其制备方法和应用 |
| GB201904544D0 (en) | 2019-04-01 | 2019-05-15 | NuCana plc | Anticancer compounds |
| CN111888373A (zh) * | 2019-05-05 | 2020-11-06 | 上海医药集团股份有限公司 | 一种虫草素或其药学上可接受的盐的应用 |
| WO2023218202A2 (en) | 2022-05-12 | 2023-11-16 | NuCana plc | Cancer treatment |
| CN115181148B (zh) * | 2022-07-12 | 2023-07-14 | 南京工业大学 | 一种基于虫草素经衍生化具有抗肿瘤效应的化合物 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4357324A (en) | 1981-02-24 | 1982-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine |
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| JP2008523082A (ja) * | 2004-12-09 | 2008-07-03 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 抗菌活性および抗癌活性を有するヌクレオチド |
| GB0505781D0 (en) | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| WO2006121820A1 (en) * | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| PE20120013A1 (es) | 2009-01-09 | 2012-02-02 | Univ Cardiff | Fosforamidato derivados de guanosina compuestos nucleosidos para tratamiento de infecciones virales |
| CA2751458C (en) | 2009-02-06 | 2018-06-05 | Rfs Pharma, Llc | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections |
| KR20110128947A (ko) * | 2009-03-20 | 2011-11-30 | 앨리오스 바이오파마 인크. | 치환된 뉴클레오시드 및 뉴클레오티드 유사체 |
| US9090642B2 (en) | 2010-07-19 | 2015-07-28 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| CN105061534A (zh) | 2010-09-22 | 2015-11-18 | 艾丽奥斯生物制药有限公司 | 取代的核苷酸类似物 |
| US20120070411A1 (en) * | 2010-09-22 | 2012-03-22 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| GB201016855D0 (en) | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| HUE029022T2 (en) | 2011-03-01 | 2017-02-28 | Nucana Biomed Ltd | Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer |
| EP2776438A4 (en) * | 2011-11-10 | 2015-04-29 | Inhibitex Inc | SUBSTITUTED PURIN NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR THE TREATMENT OF VIRUS INFECTIONS |
| JP6762873B2 (ja) * | 2013-09-11 | 2020-09-30 | エモリー・ユニバーシテイ | ヌクレオチドおよびヌクレオシド組成物ならびにこれらに関連する使用 |
| JP2017504572A (ja) | 2013-11-27 | 2017-02-09 | アイデニクス・ファーマシューティカルズ・エルエルシー | 肝臓癌治療のためのヌクレオチド類 |
| SI3119794T1 (en) | 2014-06-25 | 2018-02-28 | NuCana plc | FORMULATION, COMPOSITION OF GEMCITABIN PREPARED |
| CN105646629A (zh) | 2014-11-25 | 2016-06-08 | 广州市恒诺康医药科技有限公司 | L-核苷类化合物及其应用 |
| MX2017006942A (es) | 2014-11-28 | 2017-08-24 | Nucana Biomed Ltd | Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer. |
| WO2016145142A1 (en) | 2015-03-10 | 2016-09-15 | Emory University | Nucleotide and nucleoside therapeutics compositions and uses related thereto |
| KR20180021697A (ko) | 2015-05-14 | 2018-03-05 | 뉴카나 피엘씨 | 암 치료 |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201609602D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
-
2015
- 2015-11-27 MX MX2017006942A patent/MX2017006942A/es active IP Right Grant
- 2015-11-27 CN CN201580063936.1A patent/CN107207554B/zh active Active
- 2015-11-27 EP EP19181028.2A patent/EP3683225A1/en active Pending
- 2015-11-27 RS RSP20191057 patent/RS59264B1/sr unknown
- 2015-11-27 MX MX2020010375A patent/MX2020010375A/es unknown
- 2015-11-27 LT LTEP15804216.8T patent/LT3224268T/lt unknown
- 2015-11-27 HU HUE15804216A patent/HUE046850T2/hu unknown
- 2015-11-27 SI SI201530848T patent/SI3224268T1/sl unknown
- 2015-11-27 EA EA201791182A patent/EA031727B1/ru unknown
- 2015-11-27 US US15/518,527 patent/US10570168B2/en active Active
- 2015-11-27 IL IL291927A patent/IL291927A/en unknown
- 2015-11-27 JP JP2017528423A patent/JP6646668B2/ja active Active
- 2015-11-27 PL PL15804216T patent/PL3224268T3/pl unknown
- 2015-11-27 AU AU2015352203A patent/AU2015352203B2/en active Active
- 2015-11-27 SG SG11201702369UA patent/SG11201702369UA/en unknown
- 2015-11-27 PT PT15804216T patent/PT3224268T/pt unknown
- 2015-11-27 KR KR1020237021261A patent/KR20230098915A/ko not_active Application Discontinuation
- 2015-11-27 ES ES15804216T patent/ES2742167T3/es active Active
- 2015-11-27 DK DK15804216.8T patent/DK3224268T3/da active
- 2015-11-27 ME MEP-2019-230A patent/ME03462B/me unknown
- 2015-11-27 CA CA2962373A patent/CA2962373C/en active Active
- 2015-11-27 KR KR1020177014174A patent/KR102548806B1/ko active IP Right Grant
- 2015-11-27 SG SG10202009020VA patent/SG10202009020VA/en unknown
- 2015-11-27 CN CN202010794701.2A patent/CN111909231A/zh active Pending
- 2015-11-27 EP EP15804216.8A patent/EP3224268B1/en active Active
- 2015-11-27 WO PCT/GB2015/053628 patent/WO2016083830A1/en active Application Filing
-
2017
- 2017-03-23 IL IL251353A patent/IL251353B/en active IP Right Grant
- 2017-05-23 PH PH12017500944A patent/PH12017500944A1/en unknown
- 2017-05-24 CL CL2017001336A patent/CL2017001336A1/es unknown
- 2017-05-26 MX MX2022008744A patent/MX2022008744A/es unknown
-
2019
- 2019-08-13 HR HRP20191461 patent/HRP20191461T1/hr unknown
- 2019-08-13 CY CY20191100874T patent/CY1122074T1/el unknown
- 2019-09-20 AU AU2019232929A patent/AU2019232929B2/en active Active
-
2020
- 2020-01-10 JP JP2020002722A patent/JP6978524B2/ja active Active
- 2020-02-05 US US16/782,952 patent/US11352387B2/en active Active
- 2020-07-16 IL IL276109A patent/IL276109B/en unknown
-
2022
- 2022-04-07 IL IL292062A patent/IL292062B2/en unknown
- 2022-06-06 US US17/833,780 patent/US20220306675A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191461T1 (hr) | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja | |
| HRP20201264T1 (hr) | Prolijekovi gemcitabina | |
| HRP20202073T1 (hr) | Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori | |
| HRP20150952T1 (hr) | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe | |
| HRP20230400T1 (hr) | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 | |
| HRP20210212T1 (hr) | Triciklični spoj kao antikancerogeni agensi | |
| MY198880A (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
| HRP20180158T1 (hr) | Spojevi biarilamida kao inhibitori kinaze | |
| HRP20180762T1 (hr) | Liječenje karcinoma | |
| MX2023008994A (es) | Derivados de pirazina fusionados como inhibidores de a2a/a2b. | |
| MX2016006919A (es) | Nucleotidos para el tratamiento de cancer de higado. | |
| MX2022010703A (es) | Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores. | |
| TN2017000486A1 (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| SA515370134B1 (ar) | تركيبة صيدلانية تحتوي على عامل علاجي قائم على الهيموغلوبين المعدل لعلاج السرطان المستهدف والتصوير التشخيصي | |
| MD20160016A2 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| JP2019521971A5 (hr) | ||
| NZ726365A (en) | Combinations for treating cancers | |
| NZ722345A (en) | Pyrazolone compounds and uses thereof | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| BR112018006157A2 (pt) | derivados de imidazo[4,5-b]piridina como inibidores duplos de dyrk1/clk1 | |
| MX2018003685A (es) | Moleculas tipo esfingolipidos sinteticas, farmacos, metodos de su sintesis y metodos de tratamiento. | |
| BR112018012458A2 (pt) | ?composições farmacêuticas que compreendem o derivado da fenilaminopirimidina? | |
| WO2018054989A9 (en) | Benzoimidazole derivatives as anticancer agents | |
| HRP20191227T1 (hr) | Derivat 4-(3-pirazolilamino)benzimidazola kao inhibitor jak1, namijenjen liječenju raka |